Thrombotic Microangiopathy Clinical Trial
Official title:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ravulizumab in Adult and Adolescent Participants Who Have Thrombotic Microangiopathy (TMA) After Hematopoietic Stem Cell Transplant (HSCT)
This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab in adult and adolescent participants with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). In Stage 1, an open-label, single-arm period, the dosing regimen will be confirmed. In Stage 2, participants will be randomized to receive either blinded ravulizumab plus best supportive care or matching placebo plus best supportive care. The treatment period is 26 weeks (open-label for Stage 1, and randomized, double-blind, and placebo-controlled for Stage 2) followed by a 26-week follow-up period.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02604420 -
Identification and Treatment of Thrombotic Microangiopathies in Allogeneic Stem Cell Transplants
|
||
| Recruiting |
NCT04557735 -
Study of Ravulizumab in Pediatric Participants With HSCT-TMA
|
Phase 3 | |
| Terminated |
NCT04743804 -
Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger
|
Phase 3 | |
| Recruiting |
NCT04845022 -
Incidence of Snakebite Associated Thrombotic Microangiopathy & Role of Peripheral Blood Smear as a Predictor of Clinical Outcome
|
||
| Terminated |
NCT00593229 -
International Registry and Biorepository for TMA(Thrombotic Microangiopathy)
|
N/A | |
| Recruiting |
NCT05991245 -
French National Cohort MATRIX "Renal and Systemic Thrombotic Microangiopathy"
|
||
| Terminated |
NCT00726544 -
Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy
|
Phase 2 | |
| Available |
NCT02355782 -
OMS721 Compassionate Use in Patients With Thrombotic Microangiopathy
|
N/A |